cerrar
Tagged with Opinion

Aligning Combination Product Regulations in Asia-Pacific: A…
Writing in the April edition of DIA’s Global Forum magazine, Dhiraj Behl, Janine Jamieson, and Harikesh Kalonia highlight some of the regulatory…

Importance of Reliance to Support Strengthening Latin American…
Writing in the April edition of DIA’s Global Forum magazine, Maria Cristina Mota Pina of Abbvie on behalf of FIFARMA Regulatory & Biologics…

Can Europe’s Beating Cancer Plan Make it an Innovation…
The EFPIA’s Nathalie Moll outlines the significance of Europe’s Beating Cancer Plan to cancer patients in Europe, and its potential to boost the…

Latvia: Striving to Catch Up to its Neighbours on Innovation…
Dr Valters Bolevics, director general of the Association of International Research-based Pharmaceuticals Manufacturers of Latvia (SIFFA), outlines the…

Canada: Federal Consultations on a National Strategy for Rare…
Writing in the March edition of DIA’s Global Forum magazine, Judith Glennie examines the findings of Health Canada's consultation with Canadians on…

Accelerated Regulatory Assessment of Innovative Medicines in…
Writing in the March edition of DIA’s Global Forum magazine, EMD Serono's Ana Padua outlines the findings of a recent study into accelerated…

Public Insurance Coverage for Rare Disease Patients in China:…
Kevin Rufang Huang, president and founder of the Chinese Organization for Rare Disorders (CORD), outlines the findings of the first ever analysis into…

USA: 2 Things the Biden Administration can do Now to Lower Costs…
PhRMA’s Stephen J. Ubl outlines two ways in which the new US presidency can help lower healthcare costs and why biopharmaceutical companies support…

Securing the Conditions to Secure Our Meds
The AAM’s Dan Leonard highlights the savings impact that generic and biosimilar medicines have on US healthcare today and introduces the ‘Secure…

IFPMA’s Thomas Cueni on why “#TeamVaccines is all of…
Thomas Cueni of the International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) highlights the incredible progress of COVID-19…

After Brexit: Focus on the New Pharmaceutical Strategy for Europe
Writing in the February edition of DIA’s Global Forum magazine, Thomas Kühler of Sanofi R&D looks at the future of European pharma post-Brexit,…

Curing the Incurable: Cell & Gene Therapy and A New Age for…
Bayer’s Michael Levy casts his eye over the implications of the advent of cell and gene therapies on pharmacovigilance and patient safety.  Levy…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here